All articles by Swagath Bandhakavi
Swagath Bandhakavi
Swissmedic approves Norgine’s IFINWIL for paediatric HRNB
IFINWIL inhibits ornithine decarboxylase, an enzyme crucial for producing polyamines that support tumour growth.
GSK closes $2bn acquisition of efimosfermin from Boston Pharmaceuticals
Efimosfermin is in phase III as a monthly subcutaneous treatment for MASH, an advanced steatotic liver disease.
European Commission fines Alchem for breaching antitrust rules
The EC found Alchem involved in cartel activities concerning SNBB, a crucial component for Buscopan production.
Alembic acquires Utility Therapeutics to bolster antibacterial portfolio
The acquisition grants Alembic access to PIVYA, the first FDA-approved antibiotic for uncomplicated urinary tract infections in two decades.
Dizal’s Zegfrovy wins FDA approval for targeted NSCLC treatment
Zegfrovy is an oral irreversible EGFR inhibitor targeting diverse EGFR mutations with selectivity for wild-type EGFR.
Merck completes $3.4bn acquisition of SpringWorks Therapeutics
SpringWorks provides Merck with a range of therapies for rare tumours, addressing areas with limited treatment options.
AbbVie to expand RNA capabilities with $2.1bn acquisition of Capstan Therapeutics
As part of the deal, AbbVie will acquire Capstan’s candidate CPTX2309, in Phase 1 trials, and its tLNP platform for targeted RNA delivery.
Hikma Pharmaceuticals to invest $1bn to boost US medicine production
The investment aims to expand its capacity to develop and produce generic medicines essential for the US healthcare system.
KalVista and Pendopharm to collaborate on HAE candidate sebetralstat in Canada
Sebetralstat is an investigational oral plasma kallikrein inhibitor being developed as an on-demand treatment for hereditary angioedema.
Alvotech-led study finds AVT23 biosimilar matches Xolair’s therapeutic effects
The study found AVT23 therapeutically equivalent and similarly safe as the reference biologic for treating chronic spontaneous urticaria.